Beneficial effect of a novel nonsteroidal anti-inflammatory agent with basic character and antioxidant properties on experimental colitis in rats

Authors Andreadou I., Papalois A., Triantafillidis J., Demonakou M., Govosdis V., Vidali M., Anagnostakis E., Kourounakis P..


Ulcerative colitis is a chronic disorder of unknown etiology.
Conservative treatment remains empirical, even today.
The aim of this study was to test the efficacy of a novel nonsteroidal
anti-inflammatory agent {5-(2-hydroxy-ethylamino)-
1-cyclohexyl-2-pentanone} (compound A), with basic
character and antioxidant properties on an experimental
model of ulcerative colitis in rats. The effect of this compound
was compared with that of methyl-prednisolone on
the histological abnormalities and serum levels of Tumor
Necrosis Factor alpha (TNF-á© of experimental colitis produced
by 2,4,6-trinitrobenzenesulfonic acid (TNB). A total
number of 24 rats were used, randomly assigned to one of
four groups of 6 rats each. Group 1: colitis without treatment
(disease control), group 2: normal animals (control),
group 3: induction of experimental colitis treated with methylprednisolone
(5.3 x 10-3 mmol/kg i.v., every day for 7 days)
and group 4: induction of experimental colitis plus administration
of compound A (0.6 mmol/kg i.v., every day for 7
days). The administration of compound A resulted in a statistically
significant reduction (p<0.05) of the histological
damage (score) and the levels of serum TNF-ᬠcompared to controls. This beneficial effect was probably due to the
combination in a single molecule of the anti-inflammatory,
antioxidant properties and the basic character of this compound.
These results indicate that this novel non-steroidal
anti-inflammatory agent can be a possible potent therapeutic
agent for the treatment of ulcerative colitis.
Key words: basic anti-inflammatory agent, antioxidant, experimental
colitis, treatment, non-steroidal-antiinflammatory
drugs, methylprednisolone
Original Articles